

DEFINITIONS/EXPLANATIONS

- FP/STD:** This field is to be completed by sites supported by the Michigan Department of Health and Human Services that provide STD and/or Family Planning services. Completion of this field will assist us in linking tests with the correct submitter site.
- Zip Code:** Patient ZIP Code data is used to calculate screening rates in local jurisdictions and compare them to infection. The resulting information can be used to better target resources and testing.
- Sex:** Mark the current biological sex of the patient. This may differ from gender or gender identity of patient. This is a required field for all tests and is relevant to specimen source for laboratory testing.
- Pregnant:** Reporting requirement in accordance with the Notifiable Disease Rules of Michigan Public Health Code. Report Pregnancy status, if available.

- Specimen Collection:** Specimens must be collected using the appropriate collection kit as shown below. Specimens received in the wrong collection kit will not be tested and will be reported as "Unsatisfactory."
- Multi-test swabs (Orange tubes) are now FDA approved for clinician collected Rectal and Pharyngeal specimens as well as clinician and patient collected Vaginal specimens. The MDHHS lab continues to test Rectal and Pharyngeal specimens collected with Unisex swabs, however Multi-test swabs are preferred.

Specimen Source	Kit Number	Collection Kit	Tube Color
Vaginal, Pharyngeal, Rectal	2-V	Aptima Multi-test Swab	Orange
Urine	2-U	Aptima Urine Collection Kit	Yellow
Cervical, Urethral	2	Aptima Unisex Collection Kit	White

- Symptoms:** Patient requesting examination due to symptoms, or, symptoms discovered upon examination.
- Infected Partner:** Patient has known exposure to STD (self-reported or documented).
- Partner Risk:** Patient has multiple sex partners.
- History of STD:** Patient has been diagnosed with a sexually transmitted disease within the last 3 years.
- PrEP:** Test is run in accordance with CDC Guidelines for prescribing and monitoring a patient on Pre-Exposure Prophylaxis for HIV (PrEP).
- Age Recommended:** CDC recommends annual screening of females ≤ 24 .
- Retest:** Patients diagnosed with chlamydia and gonorrhea should be retested approximately three (3) months after treatment, regardless of whether they believe that their sex partners were treated. If retesting at three months is not possible, clinicians should retest whenever that person next presents for medical care in the twelve months following initial treatment.
- School-Wide Event:** Test is run as part of a school-wide STD screening event. This is different from screening/testing that occurs in a school-based health center.

- Patient Address:** Required for billing Private insurance.